Related Experiment Video
Updated: Feb 16, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Anemia and coronary artery disease: pathophysiology, prognosis, and treatment
Jennifer A Rymer1, Sunil V Rao
1Department of Medicine, Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute, Durham, North Carolina, USA.
Insights
Anemia in coronary artery disease (CAD) is complex. This review examines anemia
Area of Science:
- Cardiology
- Hematology
Background:
- Anemia in coronary artery disease (CAD) presents complex mechanisms, pathophysiology, and treatment challenges.
- Hemodynamic shifts in acute anemia can lead to progressive arterial wall and left ventricular hypertrophy with chronic anemia.
Purpose of the Study:
- To review anemia as an independent risk factor for CAD events and cardiovascular mortality post-percutaneous coronary intervention.
- To investigate optimal blood transfusion thresholds and strategies (liberal vs. conservative) in CAD patients.
- To evaluate the evidence for iron replacement and erythropoietin-stimulating agents in CAD patients.
Main Methods:
- Systematic review of existing literature.
- Analysis of hemodynamic changes associated with anemia.
- Evaluation of cardiovascular outcomes and mortality data.
Main Results:
- Anemia is an independent risk factor for adverse cardiovascular events and mortality after percutaneous coronary intervention.
- Evidence suggests specific thresholds for blood transfusion in CAD patients, with varying outcomes based on strategy.
- Lack of robust evidence for iron replacement in CAD; potential risks associated with erythropoietin-stimulating agents.
Conclusions:
- Anemia management in CAD requires careful consideration of transfusion strategies and risks.
- Further research is needed to clarify the role of iron and erythropoietin-stimulating agents in CAD patients with anemia.
Abstract:
The mechanisms, pathophysiology, and treatment of anemia in coronary artery disease (CAD) are complex. The hemodynamic changes found in the acute anemic state may contribute to progressive arterial wall and left ventricular hypertrophy if the anemic state persists chronically. We will examine the evidence for anemia as an independent risk factor for CAD events and cardiovascular mortality after percutaneous coronary intervention. We will also investigate the thresholds for appropriate blood transfusion in patients with CAD, as well as the cardiovascular outcomes associated with the utilization of a liberal versus conservative blood transfusion strategy. Although there is evidence supporting the use of intravenous iron replacement in patients with congestive heart failure, we will demonstrate the lack of evidence for iron replacement in patients with CAD. Finally, we will examine the evidence for increased cardiovascular mortality and venous thromboembolic events with the use of erythropoietin-stimulating agents in patients with CAD.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
13:10Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
Published on: April 24, 2017
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations